• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday

    12/27/22 4:12:07 AM ET
    $EQ
    $MTCR
    $OGEN
    $PT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $EQ alert in real time by email

    With US stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

    • Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. (NASDAQ:EQ) mutually agreed to terminate definitive merger agreement. Metacrine shares jumped 5.4% to $0.4551 in after-hours trading, while Equillium shares dropped 6.3% to close at $0.89 on Friday.
    • Oragenics, Inc. (NYSE:OGEN) disclosed a 1-for-60 reverse stock split. Oragenics shares dipped 6.7% to close at $0.1450 on Friday.

    Check out our premarket coverage here

    • Pintec Technology Holdings Limited (NASDAQ:PT) reported that its total revenues dropped by 56.53% year-over-year to RMB39.82 million ($5.93 million) for the first half of 2022. Its net loss per share came in at RMB0.41 (US$0.06). Pintec Technology shares dropped 5.9% to close at $0.46 on Friday.
    • Proterra Inc. (NASDAQ:PTRA) filed for mixed shelf of up to $500 million. Proterra shares declined 1.9% to close at $4.11 on Friday.

    Read This Next: $4.8 Million Bet On America's Car-Mart? Check Out These 3 Stocks Insiders Are Buying

    Get the next $EQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EQ
    $MTCR
    $OGEN
    $PT

    CompanyDatePrice TargetRatingAnalyst
    Equillium Inc.
    $EQ
    2/25/2026$5.00Buy
    Stifel
    Equillium Inc.
    $EQ
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    Proterra Inc.
    $PTRA
    8/8/2023Buy → Neutral
    BTIG Research
    Proterra Inc.
    $PTRA
    10/17/2022$7.00Buy
    BTIG Research
    Proterra Inc.
    $PTRA
    9/29/2022$9.00Buy
    Truist
    Proterra Inc.
    $PTRA
    6/2/2022$10.00Buy
    DA Davidson
    Proterra Inc.
    $PTRA
    5/13/2022$12.25 → $5.00Buy → Underperform
    BofA Securities
    Proterra Inc.
    $PTRA
    3/10/2022$11.00 → $8.00Equal-Weight
    Barclays
    More analyst ratings

    $EQ
    $MTCR
    $OGEN
    $PT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. Vice President and COO Zedelmayer Christine sold $328,104 worth of shares (185,937 units at $1.76) and exercised 185,937 shares at a strike of $0.76 (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    2/23/26 12:52:51 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Telling Fred sold $198 worth of shares (210 units at $0.94), decreasing direct ownership by 18% to 948 units (SEC Form 4)

    4/A - ORAGENICS INC (0001174940) (Issuer)

    1/22/26 1:04:30 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CSO Connelly Stephen

    4 - Equillium, Inc. (0001746466) (Issuer)

    1/9/26 5:52:35 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    $MTCR
    $OGEN
    $PT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Equillium with a new price target

    Stifel initiated coverage of Equillium with a rating of Buy and set a new price target of $5.00

    2/25/26 7:52:10 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Equillium from Outperform to Market Perform and set a new price target of $1.00 from $3.00 previously

    3/28/25 8:14:37 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Proterra downgraded by BTIG Research

    BTIG Research downgraded Proterra from Buy to Neutral

    8/8/23 6:24:55 AM ET
    $PTRA
    Auto Manufacturing
    Consumer Discretionary

    $EQ
    $MTCR
    $OGEN
    $PT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $EQ
    $MTCR
    $OGEN
    $PT
    SEC Filings

    View All

    Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

    LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a po

    2/25/26 8:30:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to

    2/2/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

    Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the "Company"), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executives) is a clinical research conference being held February 2–5, 2026, in Orlando, Florida. "Oragenics is excited to participate in one of the premier global conferences for clinical operations and optimal t

    2/2/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Equillium Inc.

    SCHEDULE 13G/A - Equillium, Inc. (0001746466) (Subject)

    2/6/26 4:32:05 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Oragenics Inc.

    S-3 - ORAGENICS INC (0001174940) (Filer)

    1/22/26 4:11:24 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    1/22/26 4:05:42 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    $MTCR
    $OGEN
    $PT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 3:59:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    $MTCR
    $OGEN
    $PT
    Leadership Updates

    Live Leadership Updates

    View All

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

    SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

    2/24/25 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

    SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

    1/21/25 8:15:00 AM ET
    $MEDS
    $OGEN
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $EQ
    $MTCR
    $OGEN
    $PT
    Financials

    Live finance-specific insights

    View All

    Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

    Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

    3/27/25 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Maintains Rights to Itolizumab Following Ono Partnership

    Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

    10/31/24 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Proterra Announces Strategic Initiatives to Strengthen Financial Position and Sharpen Technology Focus

    Files for Voluntary Chapter 11 Reorganization to Maximize Value of the Business & Product Line PotentialCompany Continues to Operate as a Leading Commercial Vehicle EV Technology Provider BURLINGAME, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Proterra Inc (NASDAQ:PTRA) ("Proterra" or the "Company"), a leading innovator in commercial vehicle electrification technology, today announced that the Company is taking action to maximize the value of its business and enhance the potential of each of its product lines. To do so, Proterra has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the District of Delaware in an effort to strengthen its financial position thr

    8/7/23 5:35:16 PM ET
    $PTRA
    Auto Manufacturing
    Consumer Discretionary